\"Routine Assessment Of On-Clopidogrel Platelet Reactivity And Gene Polymorphisms In Predicting Clinical Outcome Following Drug-Eluting Stent Implantation In Patients With Stable Coronary Artery Disease\" JACC: Cardiovascular Interventions, (Articolo in rivista)

Type
Label
  • \"Routine Assessment Of On-Clopidogrel Platelet Reactivity And Gene Polymorphisms In Predicting Clinical Outcome Following Drug-Eluting Stent Implantation In Patients With Stable Coronary Artery Disease\" JACC: Cardiovascular Interventions, (Articolo in rivista) (literal)
Anno
  • 2014-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1016 (literal)
Alternative label
  • Chiara Viviani Anselmi, PhD*, Carlo Briguori, MD, PhD+ Roberta Roncarati, PhD*, ?, Laura Papa, PhD*, Gabriella Visconti, MD+, Amelia Focaccio, MD+, Francesca De Micco, PhD+, Michael V.G. Latronico§, Paolo Pagnotta, MD§, Gianluigi Condorelli, MD, PhD§ (2014)
    "Routine Assessment Of On-Clopidogrel Platelet Reactivity And Gene Polymorphisms In Predicting Clinical Outcome Following Drug-Eluting Stent Implantation In Patients With Stable Coronary Artery Disease" JACC: Cardiovascular Interventions,
    in JACC: cardiovascular interventions (Online); Elsevier, Amsterdam (Paesi Bassi)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Chiara Viviani Anselmi, PhD*, Carlo Briguori, MD, PhD+ Roberta Roncarati, PhD*, ?, Laura Papa, PhD*, Gabriella Visconti, MD+, Amelia Focaccio, MD+, Francesca De Micco, PhD+, Michael V.G. Latronico§, Paolo Pagnotta, MD§, Gianluigi Condorelli, MD, PhD§ (literal)
Pagina inizio
  • 1166 (literal)
Pagina fine
  • 1175 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://www.ncbi.nlm.nih.gov/pubmed/24262617 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • VOL. 7, , (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 10 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 4 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Istituto di Ricovero e Cura a Carattere Scientifico Multimedica, Milan, Italy Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy Istituto Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy e Istituto di Ricovero e Cura a Carattere Scientifico Multimedica, Milan, Italy Istituto di Ricovero e Cura a Carattere Scientifico Multimedica, Milan, Italy Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy Humanitas Clinical and Research Center, Rozzano, Milan, Italy Humanitas Clinical and Research Center, Rozzano, Milan, Italy Humanitas Clinical and Research Center, Rozzano, Milan, Italy and University of Milan, Milan, Italy (literal)
Titolo
  • \"Routine Assessment Of On-Clopidogrel Platelet Reactivity And Gene Polymorphisms In Predicting Clinical Outcome Following Drug-Eluting Stent Implantation In Patients With Stable Coronary Artery Disease\" JACC: Cardiovascular Interventions, (literal)
Abstract
  • Objectives This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy. Background The role of pharmacogenetics and OTR in predicting MACE--death, myocardial infarction, or stent thrombosis--in stable CAD patients scheduled for DES implantation is still debated. Methods Patients with stable CAD treated by DES implantation (n = 1,432) were genotyped with a TaqMan OpenArray (Applied Biosystems, Carlsbad, California) and assessed for OTR with the VerifyNow P2Y12 test (Accumetrics Inc., San Diego, California). Genes tested were ABCB1, CYP1A2, CYP2B6*9, CYP2C8*3, CYP2C9*2, CYP2C19, CYP3A4, CYP3A5*3, P2RY12, and PON1CYP2C19. High OTR was defined as P2Y12 reaction units >=230. The endpoint at 12-month follow-up was MACE occurring during antiplatelet therapy. Results All groups that were stratified for loss-of-function variants of the cytochrome P450 gene CYP2C19 had significant hazard ratios (HR) for MACE (genotypic HR: 1.41, 95% confidence interval [CI]: 1.06 to 1.89, p = 0.01; allelic HR: 1.56, 95% CI: 2.26 to 1.2, p = 0.01). Variants of other clopidogrel-pathway genes were not significantly associated with MACE. When OTR was assessed, clinical significance was found only in high-risk diabetic (HR: 2.11, 95% CI: 1.29 to 3.45, p < 0.001) and chronic kidney disease (HR: 2.03, 95% CI: 1.03 to 4.02, p = 0.04) patients. Conclusions CYP2C19 metabolizer status is an independent predictor of MACE after DES implantation and can be used for prognostication in all stable CAD patients. High OTR, as assessed by the VerifyNow P2Y12 test, is an independent predictor of MACE only for high-risk subsets, that is, patients with diabetes or chronic kidney disease. (literal)
Editore
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
data.CNR.it